Rheumatology Practice Management October 2018 Vol 6 No 5

“This analysis provides a framework for providers and payers evaluating the cost-effectiveness of generic celecoxib given a range of discontinuation rates, toxicity rates, and drug costs,” said Elena Losina, PhD, and colleagues.
Page 2 of 2
Results 11 - 11 of 11
  • American Health and Drug Benefits
  • Lynx CME
  • Value Based Care in Rheumatology
  • Oncology Practice Management
  • Urology Practice Management